NPR logo

ImClone

  • Download
  • <iframe src="https://www.npr.org/player/embed/1138118/138118" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
ImClone

ImClone

ImClone

  • Download
  • <iframe src="https://www.npr.org/player/embed/1138118/138118" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Last year, stocks in a small Manhattan-based biotech company, ImClone, soared on the promise of its new cancer-fighting drug, Erbitux. At the end of 2001, the Food and Drug Administration refused to accept the company's application for approval of the drug. Imclone is now facing allegations that it deliberately misled investors about the drug's status. NPR's Snigdha Prakash reports the story has now taken another turn.